GLP-1 Drug Development
Clinical development, competitive landscape, and market dynamics of GLP-1 receptor agonist medications and related obesity/diabetes drug combinations.
2 events tracked
- Single source5 days ago
Eli Lilly and Novo Nordisk pursue amylin-based treatments for obesity
Eli Lilly and Novo Nordisk are developing amylin-based obesity drugs to follow their GLP-1 successes.
CNBC
- Single source7 days ago
Eli Lilly's dual-drug obesity treatment demonstrates stronger weight reduction in Phase 2
Eli Lilly's combination obesity treatment shows improved weight loss results in mid-stage trial.
CNBC